4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-002278
Chief Business Officer sold 31,900 shares at an average $16.59 ($529,194)
- Chief Business Officer acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| McNeill Jonathan Chief Business Officer | 2024-01-02 | Sale 10b5-1 | −11,900 | $13.10 | $155,890 | 143,618 | D |
| McNeill Jonathan Chief Business Officer | 2024-01-03 | Option exercise 10b5-1 | +17,991 | $0.73 | $13,133 | 161,609 | D |
| McNeill Jonathan Chief Business Officer | 2024-01-03 | Sale 10b5-1 | −7,691 | $18.34 | $141,053 | 153,918 | D |
| McNeill Jonathan Chief Business Officer | 2024-01-03 | Sale 10b5-1 | −10,300 | $19.03 | $196,009 | 143,618 | D |
| McNeill Jonathan Chief Business Officer | 2024-01-04 | Option exercise 10b5-1 | +2,009 | $0.73 | $1,467 | 145,627 | D |
| McNeill Jonathan Chief Business Officer | 2024-01-04 | Sale 10b5-1 | −2,009 | $18.04 | $36,242 | 143,618 | D |
| Derivatives | |||||||
| McNeill Jonathan Chief Business Officer | 2024-01-03 | Option exercise · Stock option (right to buy) 10b5-1 | −17,991 | 50,537 | D | ||
| McNeill Jonathan Chief Business Officer | 2024-01-04 | Option exercise · Stock option (right to buy) 10b5-1 | −2,009 | 48,528 | D | ||
| Open-market sales · 31,900 sh · avg $16.59 · $529,194 | |||||||
Loading xslF345X05/ownership.xml…